| Stem definition | Drug id | CAS RN |
|---|---|---|
| 281 | 1405-87-4 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)
|
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 1948 | FDA | PHARMACIA AND UPJOHN |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 392.50 | 18.28 | 216 | 2698 | 310471 | 63175637 |
| Lymphatic disorder | 29.05 | 18.28 | 6 | 2908 | 375 | 63485733 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 45.19 | 20.33 | 41 | 2480 | 80488 | 34873922 |
| Renal injury | 21.22 | 20.33 | 12 | 2509 | 11183 | 34943227 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 201.47 | 16.44 | 155 | 4553 | 298761 | 79440919 |
| Lymphatic disorder | 28.23 | 16.44 | 6 | 4702 | 334 | 79739346 |
| Renal injury | 23.97 | 16.44 | 14 | 4694 | 16913 | 79722767 |
| Unevaluable event | 23.18 | 16.44 | 22 | 4686 | 55563 | 79684117 |
| Slow response to stimuli | 22.33 | 16.44 | 7 | 4701 | 1818 | 79737862 |
| Anaphylactic reaction | 22.15 | 16.44 | 26 | 4682 | 83717 | 79655963 |
| Mental status changes | 21.49 | 16.44 | 23 | 4685 | 66936 | 79672744 |
| Tachypnoea | 17.96 | 16.44 | 15 | 4693 | 32048 | 79707632 |
None
| Source | Code | Description |
|---|---|---|
| ATC | D06AX05 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use |
| ATC | J01XX10 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials |
| ATC | R02AB04 | RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Antibiotics |
| FDA PE | N0000008479 | Decreased Cell Wall Synthesis & Repair |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| CHEBI has role | CHEBI:33282 | bactericides |
| CHEBI has role | CHEBI:176497 | geroprotectors |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Keratitis | indication | 5888003 | DOID:4677 |
| Blepharoconjunctivitis | indication | 68659002 | DOID:2456 |
| Corneal abrasion | indication | 85848002 | |
| Infective blepharitis | indication | 312219000 | |
| Bacterial keratitis | indication | 314557000 | |
| Superficial Ocular Infection | indication | ||
| Minor Bacterial Skin Infections | indication | ||
| Dacryocystitis | off-label use | 85777005 | DOID:9938 |
| Corneal ulcer | off-label use | 91514001 | DOID:8463 |
| Bacterial conjunctivitis | off-label use | 128350005 | DOID:9700 |
| Meibomianitis | off-label use | 309779001 | |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Herpes simplex keratitis | contraindication | 9389005 | |
| Bacterial septicemia | contraindication | 10001005 | DOID:0040085 |
| Shock | contraindication | 27942005 | |
| Herpes simplex dendritic keratitis | contraindication | 29943008 | |
| Fungal infection of eye | contraindication | 31194008 | |
| Severe myopia | contraindication | 34187009 | |
| Tuberculosis of eye | contraindication | 49107007 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Third degree burn injury | contraindication | 80247002 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Oliguria | contraindication | 83128009 | |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Krukenberg spindle | contraindication | 85430004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Open wound | contraindication | 125643001 | |
| Eye infection | contraindication | 128351009 | |
| Seizure disorder | contraindication | 128613002 | |
| Bacterial infection of eye | contraindication | 128984004 | |
| Heart block | contraindication | 233916004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Telangiectasia disorder | contraindication | 247479008 | |
| Injury of eye region | contraindication | 282752000 | |
| Pregnancy, function | contraindication | 289908002 | |
| Viral eye infection | contraindication | 312132001 | |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Vaccinia keratitis | contraindication | 397552005 | |
| Atrophoderma | contraindication | 399979006 | |
| Peripheral vascular disease | contraindication | 400047006 | |
| Denuded skin | contraindication | 418242004 |
| Species | Use | Relation |
|---|---|---|
| Cattle | Necrotic enteritis caused or complicated by Clostridium species | Indication |
| Cattle | To increase rate of weight gain | Indication |
| Cattle | To improve feed efficiency | Indication |
| Cattle | To increases egg production | Indication |
| Chickens | Necrotic enteritis caused or complicated by Clostridium species | Indication |
| Chickens | To increase rate of weight gain | Indication |
| Chickens | Improves feed efficiency during the first seven months of production | Indication |
| Chickens | Increases egg productionduring the first seven months of production | Indication |
| Pheasants | To increase rate of weight gain | Indication |
| Pheasants | To improve feed efficiency | Indication |
| Quail | To increase rate of weight gain | Indication |
| Quail | To improve feed efficiency | Indication |
| Swine | Enteritis caused by Clostridium perfringens | Indication |
| Swine | Swine dysentery associated with Treponema hyodysenteriae | Indication |
| Swine | To increase rate of weight gain | Indication |
| Swine | To improve feed efficiency | Indication |
| Turkeys | Enteritis | Indication |
| Turkeys | To increase rate of weight gain | Indication |
| Turkeys | To improve feed efficiency | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Amprol HI-E Plus | Huvepharma EOOD | 3 |
| Albac / Deccox, Broiler Finisher Medicated | Zoetis Inc. | 2 |
| BMD 30 Granular A, BMD 50 Granular A, BMD 30, BMD 50, BMD 60 | Zoetis Inc. | 1 |
| Baciferm - 10, Baciferm - 25, Baciferm - 40, Baciferm - 50 | Zoetis Inc. | 1 |
| Coban plus Baciferm | Elanco US Inc. | 2 |
| Coban plus BMD | Elanco US Inc. | 2 |
| Coyden 25 with Bacitracin Zinc | Huvepharma EOOD | 2 |
| Bacitracin-Neomycin-Polymyxin with Hydrocortisone Acetate Ophthalmic Ointment, Vetropolycin HC Ophthalmic Ointment | Dechra, Ltd. | 4 |
| Bac-Neo-Poly Ophthalmic Ointment, Vetropolycin Ophthalmic Ointment | Dechra, Ltd. | 3 |
| Entromycin Powder | Zoetis Inc. | 2 |
| Mycitracin Sterile Ophthalmic Ointment | Zoetis Inc. | 3 |
| Soluble Fortracin Concentrate | Zoetis Inc. | 1 |
| Baciferm Soluble 50 | Zoetis Inc. | 1 |
| BMD Soluble | Zoetis Inc. | 1 |
| Cortisporin Veterinary Ophthalmic Ointment | Intervet Inc. | 4 |
| Neosporin Ophthalmic Ointment | Intervet Inc. | 3 |
| Robenz Plus Zn Bacitracin | Zoetis Inc. | 2 |
| Bac MD / Robenz | Zoetis Inc. | 2 |
| Nicarbazin / Bacitracin Premix | Phibro Animal Health Corp. | 2 |
| Albac 50 Type A Medicated Article | Zoetis Inc. | 1 |
| BMD and Coyden 25 | Huvepharma EOOD | 2 |
| Avatec / Fortracin Premix | Zoetis Inc. | 2 |
| Baciferm / Amprol HI-E Premix | Zoetis Inc. | 3 |
| Albac / Coban | Zoetis Inc. | 2 |
| Bio-Cox / BMD | Zoetis Inc. | 2 |
| Coban / BMD | Zoetis Inc. | 2 |
| Baciferm / Bio-Cox | Zoetis Inc. | 2 |
| BMD / Stenorol | Huvepharma EOOD | 2 |
| BMD / Monteban | Zoetis Inc. | 2 |
| Baciferm / Albac, Baciferm / Monteban | Zoetis Inc. | 2 |
| BMD / Stenorol | Huvepharma EOOD | 2 |
| BMD / Maxiban | Elanco US Inc. | 3 |
| BMD / Coban | Elanco US Inc. | 2 |
| BMD and ChlorMax | Zoetis Inc. | 2 |
| Aviax / BMD | Phibro Animal Health Corp. | 2 |
| Avatec / Baciferm | Zoetis Inc. | 2 |
| BMD / Zoamix | Zoetis Inc. | 2 |
| BMD / Ivomec Premix for Swine | Boehringer lngelheim Animal Health USA Inc. | 2 |
| BMD / Deccox | Zoetis Inc. | 2 |
| Avatec / Baciferm | Zoetis Inc. | 2 |
| BMD / Maxiban | Zoetis Inc. | 3 |
| BMD and Zoamix | Zoetis Inc. | 2 |
| Bio-Cox / BMD | Zoetis Inc. | 2 |
| Pennitracin MD 50G | Pharmgate Inc. | 1 |
| BMD / Coban | Zoetis Inc. | 2 |
| BMD / Safe-Guard | Zoetis Inc. | 2 |
| Nicarb / Baciferm | Phibro Animal Health Corp. | 2 |
| Clinacox and BMD | Elanco US Inc. | 2 |
| BMD / Robenz | Zoetis Inc. | 2 |
| Amprol / BMD | Zoetis Inc. | 2 |
| Avatec / BMD | Zoetis Inc. | 2 |
| Avatec / Albac | Zoetis Inc. | 2 |
| Clinacox and BMD | Elanco US Inc. | 2 |
| Nicarb 25% plus BMD | Zoetis Inc. | 2 |
| Pennitracin MD and Maxiban | Pharmgate Inc. | 3 |
| Pennitracin MD and Coban | Pharmgate Inc. | 2 |
| BMD / Sacox | Huvepharma EOOD | 2 |
| Baciferm / Sacox | Huvepharma EOOD | 2 |
| BMD / Nicarmix 25 | Planalquimica Industrial Ltda. | 2 |
| Albac / Bio-Cox | Zoetis Inc. | 2 |
| Albac / Amprol Hi-E | Zoetis Inc. | 3 |
| Albac / Sacox | Zoetis Inc. | 2 |
| Albac / Robenz | Zoetis Inc. | 2 |
| Albac / Deccox | Zoetis Inc. | 2 |
| Albac / Coyden 25 | Zoetis Inc. | 2 |
| Albac 50 Type A Medicated Article | Zoetis Inc. | 1 |
| BMD-25, -30, -40, -50, -60, or -75 / Aureomycin -50, -70, -80, -90 or -100 | Zoetis Inc. | 2 |
| BMD Pennchlor | Pharmgate Inc. | 2 |
| Albac 50 plus Nicarb | Zoetis Inc. | 2 |
| Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment | Akorn Animal Health Inc. | 3 |
| ZoaShield and BMD | Elanco US Inc. | 2 |
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Kinase | IC50 | 5.27 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.72 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.87 | DRUG MATRIX | |||||
| Undecaprenyl-diphosphatase | Unclassified | IC50 | 5.25 | CHEMBL |
| ID | Source |
|---|---|
| 4017493 | VUID |
| N0000145879 | NUI |
| D00128 | KEGG_DRUG |
| 1405-89-6 | SECONDARY_CAS_RN |
| 11417 | RXNORM |
| C0004599 | UMLSCUI |
| CHEBI:28669 | CHEBI |
| CHEMBL1200558 | ChEMBL_ID |
| CHEMBL2096639 | ChEMBL_ID |
| D001414 | MESH_DESCRIPTOR_UI |
| DB00626 | DRUGBANK_ID |
| 1167 | INN_ID |
| 55852-84-1 | SECONDARY_CAS_RN |
| 58H6RWO52I | UNII |
| 4241 | MMSL |
| 4242 | MMSL |
| 4917 | MMSL |
| 6046 | MMSL |
| 7622 | MMSL |
| d01115 | MMSL |
| 31707003 | SNOMEDCT_US |
| 370330005 | SNOMEDCT_US |
| 5220000 | SNOMEDCT_US |
| 96009006 | SNOMEDCT_US |
| CHEMBL2108831 | ChEMBL_ID |
| 4017493 | VANDF |
| 4018101 | VANDF |
| 10909430 | PUBCHEM_CID |
| 002798 | NDDF |
| 002799 | NDDF |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Good Sense First Aid Antibiotic | HUMAN OTC DRUG LABEL | 3 | 0113-0084 | OINTMENT | 400 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| Good Sense Triple Antibioticand Pain Relief | HUMAN OTC DRUG LABEL | 4 | 0113-0679 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| basic care first aid antibiotic | HUMAN OTC DRUG LABEL | 3 | 0113-0701 | OINTMENT | 400 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| good sense triple antibiotic | HUMAN OTC DRUG LABEL | 4 | 0113-1140 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| Basic Care First Aid Antibiotic Plus Pain Relief | HUMAN OTC DRUG LABEL | 4 | 0113-7679 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| Bacitracin Zinc and Polymyxin B Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0168-0273 | OINTMENT | 500 1 | OPHTHALMIC | ANDA | 17 sections |
| Kaiser PermanenteDouble antibiotic | HUMAN OTC DRUG LABEL | 2 | 0179-8707 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 14 sections |
| AntibioticMaximum Strength | HUMAN OTC DRUG LABEL | 3 | 0363-0018 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 13 sections |
| AntibioticMaximum Strength | HUMAN OTC DRUG LABEL | 3 | 0363-0018 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 13 sections |
| Bacitracin | HUMAN OTC DRUG LABEL | 1 | 0363-0075 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 14 sections |
| Triple Antibiotic with Pain ReliefMaximum Strength | HUMAN OTC DRUG LABEL | 4 | 0363-0123 | OINTMENT | 500 [USPU] | TOPICAL | OTC MONOGRAPH FINAL | 13 sections |
| Triple Antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0179 | OINTMENT | 400 [iU] | TOPICAL | OTC monograph final | 13 sections |
| Triple Antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0179 | OINTMENT | 400 [iU] | TOPICAL | OTC monograph final | 13 sections |
| Triple Antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0179 | OINTMENT | 400 [iU] | TOPICAL | OTC monograph final | 13 sections |
| triple antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0539 | OINTMENT | 400 [USPU] | TOPICAL | OTC monograph final | 15 sections |
| triple antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0539 | OINTMENT | 400 [USPU] | TOPICAL | OTC monograph final | 15 sections |
| triple antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-0539 | OINTMENT | 400 [USPU] | TOPICAL | OTC monograph final | 15 sections |
| First Aid Antibiotic | HUMAN OTC DRUG LABEL | 4 | 0363-0841 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| First Aid Antibiotic | HUMAN OTC DRUG LABEL | 4 | 0363-0841 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 13 sections |
| Walgreens Triple Antibiotic | HUMAN OTC DRUG LABEL | 3 | 0363-2016 | OINTMENT | 400 [iU] | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
| Walgreens Bacitracin Zinc | HUMAN OTC DRUG LABEL | 1 | 0363-2075 | OINTMENT | 500 [USPU] | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
| Triple Antibiotic | HUMAN OTC DRUG LABEL | 4 | 0363-2900 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 13 sections |
| Triple Antibiotic | HUMAN OTC DRUG LABEL | 4 | 0363-2900 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 13 sections |
| Walgreens Maximum Strength Triple Antibiotic With Pain Relief | HUMAN OTC DRUG LABEL | 4 | 0363-7872 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 11 sections |
| Walgreens Wal-Sporin First Aid Antibiotic | HUMAN OTC DRUG LABEL | 2 | 0363-8821 | OINTMENT | 500 [USPU] | TOPICAL | OTC monograph final | 12 sections |
| Triple Antibiotic Plus Pain Relief | HUMAN OTC DRUG LABEL | 4 | 0363-8888 | OINTMENT | 500 [USPU] | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
| Bacitracin Zinc, Neomycin Sulfate, and Polymyxin B Sulfate | HUMAN OTC DRUG LABEL | 3 | 0404-0167 | OINTMENT | 400 [iU] | TOPICAL | OTC monograph final | 12 sections |
| Bacitracin Zinc | HUMAN OTC DRUG LABEL | 1 | 0404-0170 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 14 sections |
| Bacitracin Zinc, Polymyxin B Sulfate, and Neomycin Sulfate | HUMAN OTC DRUG LABEL | 3 | 0404-0171 | OINTMENT | 400 [iU] | TOPICAL | OTC monograph final | 12 sections |
| Bacitracin Zinc | HUMAN OTC DRUG LABEL | 1 | 0404-0172 | OINTMENT | 500 [iU] | TOPICAL | OTC monograph final | 14 sections |